Abstract CT267: Temsirolimus (T) in patients (pts) with solid tumors with AKT1/3 amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Deepti Behl, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Niklas Mackler, Herbert L. Duvivier, Philip J. Gold, Sapna R. Patel, Regan M. Duffy, Lauren A. Mauro, Eugene R. Ahn, Maria Bell, Carmen J. Calfa, Jean L. Grem, Jens Rueter, Margaret von Mehren, Gina N. Grantham, Abigail Gregory, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky
Institutions: Sutter Medical Center, American Society of Clinical Oncology, Michigan Cancer Research Consortium, Swedish Medical Center, Providence Portland Medical Center, Sanford Health, University of Miami, Sylvester Comprehensive Cancer Center, Nebraska Medical Center, University of Nebraska Medical Center, Jackson Laboratory, Fox Chase Cancer Center, Duke University, Duke Medical Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4393989666